Cancer Research and Treatment

Kyung-Ha Ryu

1 Article

Effect on Cell Cycle Progression by N-Myc Knockdown in SK-N-BE(2) Neuroblastoma Cell Line and Cytotoxicity with STI-571 Compound: Un-Young Yu, Je-Eun Cha, Sun-Young Ju, Kyung-Ah Cho, Eun-Sun Yoo, Kyung-Ha Ryu, So-Youn Woo; Cancer Res Treat. 2008;40(1):27-32. Published online March 31, 2008; DOI: https://doi.org/10.4143/crt.2008.40.1.27

Purpose

Neuroblastoma is a common tumor in childhood, and generally exhibits heterogeneity and a malignant progression. MYCN expression and amplification profiles frequently correlate with therapeutic prognosis. Although it has been reported that MYCN silencing causes differentiation and apoptosis in human neuroblastoma cells, MYCN expression influences the cytotoxic potential of chemotherapeutic drugs via the deregulation of the cell cycle. STI-571 may constitute a promising therapeutic agent against neuroblastoma, particularly in cases in which c-Kit is expressed preferentially in MYCN-amplified neuroblastoma.

Materials and Methods

To determine whether STI-571 exerts a synergistic effect on cytotoxicity with MYCN expression, we assessed apoptotic cell death and cell cycle distribution after 72 h of exposure to STI-571 with or with out treatment of SK-N-BE(2) neuroblastoma cells with MYCN siRNA.

Results

MYCN siRNA-treated SK-N-BE(2) cells did not affect apoptosis and cells were arrested in G0/G1 phase after STI-571 treatment.

Conclusions

siRNA therapy targeted to MYCN may not be effective when administered in combination with STI-571 treatment in cases of neuroblastoma. Therefore, chemotherapeutic drugs that target S or G2-M phase may prove ineffective when applied to cells arrested in the G0/1 phase as the result of MYCN knockdown and STI-571 treatment.

Citations

Citations to this article as recorded by

Subtype of Neuroblastoma Cells with High KIT Expression Are Dependent on KIT and Its Knockdown Induces Compensatory Activation of Pro-Survival Signaling
Timofey Lebedev, Anton Buzdin, Elmira Khabusheva, Pavel Spirin, Maria Suntsova, Maxim Sorokin, Vladimir Popenko, Petr Rubtsov, Vladimir Prassolov
International Journal of Molecular Sciences.2022; 23(14): 7724. CrossRef
The Mechanism by Which MYCN Amplification Confers an Enhanced Sensitivity to a PCNA-Derived Cell Permeable Peptide in Neuroblastoma Cells
Long Gu, Peiguo Chu, Robert Lingeman, Heather McDaniel, Steven Kechichian, Robert J. Hickey, Zheng Liu, Yate-Ching Yuan, John A. Sandoval, Gregg B. Fields, Linda H. Malkas
EBioMedicine.2015; 2(12): 1923. CrossRef
Comparative analysis of gene expression: Targeted antitumor therapy in neuroblastoma cell lines
T. D. Lebedev, P. V. Spirin, N. N. Orlova, M. M. Prokofjeva, V. S. Prassolov
Molecular Biology.2015; 49(6): 939. CrossRef
A PCNA-Derived Cell Permeable Peptide Selectively Inhibits Neuroblastoma Cell Growth
Long Gu, Shanna Smith, Caroline Li, Robert J. Hickey, Jeremy M. Stark, Gregg B. Fields, Walter H. Lang, John A. Sandoval, Linda H. Malkas, Anja-Katrin Bielinsky
PLoS ONE.2014; 9(4): e94773. CrossRef
SUMOylation of Myc-Family Proteins
Arianna Sabò, Mirko Doni, Bruno Amati, Ramin Massoumi
PLoS ONE.2014; 9(3): e91072. CrossRef
Conditional expression of retrovirally delivered anti-MYCN shRNA as an in vitro model system to study neuronal differentiation in MYCN-amplified neuroblastoma
Jørn R Henriksen, Bjørn Helge Haug, Jochen Buechner, Ellen Tømte, Cecilie Løkke, Trond Flaegstad, Christer Einvik
BMC Developmental Biology.2011;[Epub] CrossRef

9,439 View
67 Download
6 Crossref

Author index